Research Article
Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists
Table 1
Baseline characteristics.
| BASELINE CHARACTERISTICS (N=53) |
| Age, median (range) years | 79 (56-93) |
| Sex (female) | 26 (42%) |
| Previous mRS N (%) | | (i) 0-3 | 41 (91%) | (ii) 4-5 | 4 (9%) |
| Arterial hypertension N (%) | 4 (9%) |
| Diabetes mellitus N (%) | 13 (25%) |
| Dyslipidemia N (%) | 23 (43%) |
| Previous stroke: | | (i) TIA N (%) | 7 (13.21%) | (ii) Ischaemic N (%) | 2 (5%) | (iii) Haemorrhagic N (%) | 3 (6.5%) | (iv) Both N (%) | 2 (5%) |
| HASBLED median (p25-p75) | 2.5 (2-3) |
| CHAD2S2-VASc median (p25-p75) | 4 (3-5) |
| Condition requiring anticoagulation: | | (i) Atrial fibrillation N (%) | 48 (90.6%) | (ii) Mechanical heart valves N (%) | 5 (9.4%) |
| Concomitant medications: | | (i) Antiplatelet agents N (%) | 3 (6.5%) | (ii) Statins N (%) | 19 (43.2%) |
| Leukoaraiosis N (%) | 24 (47%) |
|
|
TIA: transient ischaemic attack. VKA: vitamin K antagonist.
|